Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

Coronary Artery Disease Clinical Trial

— OMPA-CAD  

Official title:

Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01086163
• Other study ID #: HD-Oma-09/27D
• Status: Not yet recruiting
• Phase: N/A
• First received: March 11, 2010
• Last updated: March 11, 2010
• Start date: October 2010
• Est. completion date: April 2011

Study information

• Verified date: March 2010
• Source: HeartDrug Research LLC
• Contact: Ilya Pokov, BS
• Phone: 410-371-6204
• Email: pokov3[@]comcast.net
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Omacor®/Lovaza® is an effective, and very safe mix of PO-3A, and the drug is currently approved by the Federal authorities for the drug management of post-infarction patients with high blood triglycerides. Given the growing length of CAD progression, it is pertinent that many more patients will yield extra benefit from Lovaza® on top of aggressive antiplatelet regimens and statin due to severity of their vascular disease. Therefore, mild antiplatelet properties of PO-3A will be a highly desirable and attractive commodity of this medication.

The investigators believe that Omacor®/Lovaza® is ideally positioned for the chronic management of CAD as a safe, efficient, and "gentle" agent with no harmful interactions with statins or aspirin.

The investigators hypothesize that addition of Omacor may add mild antiplatelet protection for CAD patients.

The study objectives are:

• To assess the ex vivo effects of Omacor® on platelet function in patients with coronary artery disease (CAD).

• To compare ex vivo platelet-related effects after 7 and 14 days of therapy with Omacor and statin combination versus statin alone in patients with chronic stable coronary heart disease.

• To establish the relation of changes in platelet activity (if any) with the lipid profile to prove an additional benefit of Omacor® on top of statin and aspirin.

Description:

In terms of incidence, prevalence, morbidity, and economic costs, coronary artery disease represents a number 1 public health concern. Omacor®/Lovaza® is an effective, and very safe mix of PO-3A, and the drug is currently approved by the Federal authorities for the drug management of post-infarction patients with high blood triglycerides. Despite significant progress in the prevention and treatment of vascular disease in the Western World in the past two decades, national statistics indicate that the incidence and prevalence of heart disease has been increasing steadily. Given the growing length of CAD progression, it is pertinent that many more patients will yield extra benefit from Lovaza® on top of aggressive antiplatelet regimens and statin due to severity of their vascular disease. Therefore, mild antiplatelet properties of PO-3A will be a highly desirable and attractive commodity of this medication.

We believe that Omacor®/Lovaza® is ideally positioned for the chronic management of CAD as a safe, efficient, and "gentle" agent with no harmful interactions with statins or aspirin. Also considering low clinical incidence of aspirin-induced interactions with other classes of drugs, Lovaza® may fit nicely into a standard cocktail for diabetes, hypertension, depression, arrhythmias, and heart failure management of CAD patients, which will expand the drug utilization. However, platelet-related effects of Lovaza® on top of aspirin and statin in patients with stable coronary disease are not known, but may be important due to the high incidence of aspirin resistance and heavy burden of thrombin activation in such patients. We have a large pool of patients with documented CAD (300-350/annum), and we will be able to enroll relatively large amount of quality patients fast.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: April 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years to 60 Years

Eligibility

Inclusion Criteria:

• Stable documented coronary artery disease proven by angiography treated with statin and aspirin. In order to achieve homogeneity within this population, the following additional inclusion criteria will apply:

• survived first-time AMI more than 12 mths ago

• stable medical treatment during the last 3 months (except removal of Plavix)

• Ethnicity: Caucasians

• Males, 50 - 60 yrs

• Non-diabetics

• Excluded are those who eat more than one meal of fish / week

• Excluded are those who take omega-3 supplements of any sorts

Exclusion Criteria:

• Thrombolytic therapy or GP IIb/IIIa inhibitor within 30 days of enrollment

• Platelet count < 100,000

• History of bleeding disorder

• Hct < 30, serum creatinine =3 mg/dL, liver impairment defined as ALT/AST > 3 times upper limit of normal.

• Glomerular filtration rate <50ml/min

• Admission for acute vascular syndrome (unstable angina, MI, stroke), revascularization procedure with stent placement, or other major coronary/cerebrovascular event within 30 days.

• Active participation in other investigational drug or device trial within the last 30 days.

• Allergy or intolerance to any of the study medications.

• Antiplatelet agent other than aspirin or

• Insulin therapy

• Cancer of any localization

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Hypertriglyceridemia
• Myocardial Ischemia

Intervention

Drug:
• Omacor, omega-3 fatty acids in CAD patients
Omacor 1g versus 2g daily versus placebo

Locations

Country	Name	City	State
United States	Victor Serebruany	Towson	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
HeartDrug Research LLC	University of Oslo

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in platelet aggregation after Lovaza® (1 or 2g/daily) in patients treated with aspirin + simvastatin versus those matched patients treated with placebo+aspirin +simvastatin in combination.		Day 7 and Day 14	No
Secondary	Differences in expression of P-selectin and PAR-1 receptors after treatment with Lovaza® (1 or 2g/daily) in patients treated with aspirin + simvastatin versus those matched patients treated with placebo+aspirin +simvastatin in combination.		Day 7 and Day 14	No